Barely Significant
← all excerpts

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.

Vasc Health Risk Manag · 2017 · PMC5634378 · PMID 29042791

Europe PMCDOI
1
hedged sentence
0.0300
closest p · 0.6× alpha
0.0300
boldest claim

The sentences

nominally significantp =0.03actually significant
9 A nominally significant interaction between NYHA class at randomization and the effect of treatment was seen for the primary endpoint (better outcomes with NYHA class I–II; p =0.03; without adjustment for multiple comparisons), but not for the interaction between NYHA class and the effect on death from CV causes ( p =0.76). 9 Although the interaction is nominal, it confers a greater CV benefit to sacubitril/valsartan when initiated early in the course of HFrEF.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.